Skip to main content

Johnson & Johnson under pressure as FDA calls for pause on COVID vaccine

Morgan Stanley believes J&J news could improve the 2022 outlook for mRNA vaccine makers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.